FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

N:	25	hi	nc	ıtο	n	D	C	2	054	.9	

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number: 3235-0287										
Estimated average burden										
hours per response:										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Hannah Brendan					2. Issuer Name and Ticker or Trading Symbol Quince Therapeutics, Inc. [ QNCX ]				(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  V Officer (give title Other (specify						
(Last)	`	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/01/2024					C	below)		OFFI	below)	, I	
C/O QUINCE THERAPEUTICS, INC. 611 GATEWAY BLVD, SUITE 273					4. If Amendment, Date of Original Filed (Month/Day/Year)				Line)	6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) SOUTH FRANCI	C	A	94080								X		ed by More		rting Person One Report	ng
(City)	(S	tate)	(Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					action 2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.			ed (A) or str. 3, 4 and 5	4 and 5) Securities Beneficial Owned Fo		Form:	n: Direct In or Indirect Enstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code V	Amount	(A) o (D)	r Price	Transacti (Instr. 3 a	on(s)			15(1. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	erivative   Conversion   Date   Execution Date, ecurity   or Exercise   (Month/Day/Year)   if any		Cod	nsaction Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		ies g Security	Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Cod	de V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	J.1(3)		
Employee Stock Option (right to buy)	\$1.31	02/01/2024		A		600,000		(1)	01/31/2034	Common Stock	600,000	\$0	600,00	00	D	

## **Explanation of Responses:**

1. The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2024, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.

/s/ Brendan Hannah

02/01/2024

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.